HCC risk remains high with hep B antivirals

Chronic hepatitis B patients who achieve complete response with oral antiviral therapy are still at much higher risk of developing hepatocellular cancer compared to patients with inactive CHB, Korean researchers find.

The finding turns conventional thinking on its head as it is generally stated that successful use of oral nucleso(t)ide analogues (NUCs) decreases HCC risk, the authors from the Sungkyunkwan University School of Medicine in Seoul said.

Involving over 2300 CHB patients, the study showed 7.7% of those started on NUC therapy